Investigating Evorpacept-Based Combinations in HER2+ Breast Cancer

The ASPEN-09-03 trial is evaluating evorpacept plus trastuzumab and chemotherapy in previously treated HER2-positive metastatic breast cancer.

Javier Cortés, MD, PhD, discusses the design of the ASPEN-09-03 trial and the development of CD47 as a biomarker in pretreated HER2-positive breast cancer.

Sara A. Hurvitz, MD, FACP, discusses the mechanism of action of evorpacept and data with the agent in pretreated HER2-positive metastatic breast cancer.

Biomarker analyses indicate that CD47 expression may help predict benefit from zanidatamab plus evorpacept in HER2-positive metastatic breast cancer.